Breakthrough for kidney disease

Worldwide, 160 million people with type 2 diabetes have or are at risk of developing chronic kidney disease.

We identified the first new treatment for diabetic kidney disease in 20 years. The breakthrough treatment offers hope for hundreds of millions of people with diabetes worldwide.

Our CREDENCE trial was a randomized, double-blind, event-driven, placebo-controlled trial set in in 34 countries that enrolled 4,401 adults with type 2 diabetes.

The study aimed to compare the efficacy and safety of the drug canagliflozin versus a placebo in preventing kidney failure and cardiovascular disease in patients with diabetes and kidney disease. The early results were so compelling we were advised to stop the trial early by the Independent Data Monitoring Committee.  

Read more